UCB and Pfizer are collaborating to establish a new technology company called Cyclofluidic set up under a public-private partnership initiative by the UK’s Technology Strategy Board. It is hoped that the automated flow chemistry and flow biology techniques, to be developed by the company, will speed up and cut costs of the drug development process.